Proqr Therapeutics Eo 04 Stock Probability Of Bankruptcy

0PQ Stock  EUR 2.17  0.01  0.46%   
PROQR THERAPEUTICS's likelihood of distress is under 33% at the present time. It has slight risk of undergoing some form of financial hardship in the near future. PROQR THERAPEUTICS's Probability Of Bankruptcy is determined by interpolating and adjusting PROQR Altman Z Score to account for off-balance-sheet items and missing or unfiled public information. All items used in analyzing the odds of distress are taken from the PROQR balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out PROQR THERAPEUTICS Piotroski F Score and PROQR THERAPEUTICS Altman Z Score analysis.
  

PROQR Probability Of Bankruptcy Analysis

PROQR THERAPEUTICS's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

 = 

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current PROQR THERAPEUTICS Probability Of Bankruptcy

    
  Less than 33%  
Most of PROQR THERAPEUTICS's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PROQR THERAPEUTICS EO 04 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of PROQR THERAPEUTICS probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting PROQR THERAPEUTICS odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of PROQR THERAPEUTICS EO 04 financial health.
Please note, there is a significant difference between PROQR THERAPEUTICS's value and its price as these two are different measures arrived at by different means. Investors typically determine if PROQR THERAPEUTICS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PROQR THERAPEUTICS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
Competition

Based on the latest financial disclosure, PROQR THERAPEUTICS EO 04 has a Probability Of Bankruptcy of 33.0%. This is 23.77% lower than that of the Healthcare sector and 39.82% lower than that of the Biotechnology industry. The probability of bankruptcy for all Germany stocks is 17.15% higher than that of the company.

PROQR Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PROQR THERAPEUTICS's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PROQR THERAPEUTICS could also be used in its relative valuation, which is a method of valuing PROQR THERAPEUTICS by comparing valuation metrics of similar companies.
PROQR THERAPEUTICS is currently under evaluation in probability of bankruptcy category among related companies.

PROQR Fundamentals

About PROQR THERAPEUTICS Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze PROQR THERAPEUTICS EO 04's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PROQR THERAPEUTICS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PROQR THERAPEUTICS EO 04 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands. PROQR THERAPEUTICS is traded on Frankfurt Stock Exchange in Germany.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards PROQR THERAPEUTICS in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, PROQR THERAPEUTICS's short interest history, or implied volatility extrapolated from PROQR THERAPEUTICS options trading.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Thematic Ideas
Explore Investing Ideas  
Check out PROQR THERAPEUTICS Piotroski F Score and PROQR THERAPEUTICS Altman Z Score analysis.
You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Complementary Tools for PROQR Stock analysis

When running PROQR THERAPEUTICS's price analysis, check to measure PROQR THERAPEUTICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PROQR THERAPEUTICS is operating at the current time. Most of PROQR THERAPEUTICS's value examination focuses on studying past and present price action to predict the probability of PROQR THERAPEUTICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PROQR THERAPEUTICS's price. Additionally, you may evaluate how the addition of PROQR THERAPEUTICS to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Transaction History
View history of all your transactions and understand their impact on performance
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Please note, there is a significant difference between PROQR THERAPEUTICS's value and its price as these two are different measures arrived at by different means. Investors typically determine if PROQR THERAPEUTICS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PROQR THERAPEUTICS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.